Kang Lu

792 total citations
58 papers, 629 citations indexed

About

Kang Lu is a scholar working on Molecular Biology, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Kang Lu has authored 58 papers receiving a total of 629 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Molecular Biology, 18 papers in Pathology and Forensic Medicine and 17 papers in Immunology. Recurrent topics in Kang Lu's work include Chronic Lymphocytic Leukemia Research (14 papers), Lymphoma Diagnosis and Treatment (11 papers) and Multiple Myeloma Research and Treatments (6 papers). Kang Lu is often cited by papers focused on Chronic Lymphocytic Leukemia Research (14 papers), Lymphoma Diagnosis and Treatment (11 papers) and Multiple Myeloma Research and Treatments (6 papers). Kang Lu collaborates with scholars based in China, United States and Japan. Kang Lu's co-authors include Xin Wang, Peipei Li, Xiao Lv, Lili Feng, Xiangxiang Zhou, Na Chen, Xueling Ge, Ying Li, Xiaosheng Fang and Ping Hu and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Advanced Functional Materials.

In The Last Decade

Kang Lu

53 papers receiving 624 citations

Peers

Kang Lu
Ilaria Buondonno Italy
Kazuki Koizumi Japan
Alexander Neuwelt United States
Xiangyuan Liu China
Ken‐ichi Akamatsu United States
Michael Rosenbach United States
Thomas Plitz United States
Nan Lin China
Geng Xu China
Ilaria Buondonno Italy
Kang Lu
Citations per year, relative to Kang Lu Kang Lu (= 1×) peers Ilaria Buondonno

Countries citing papers authored by Kang Lu

Since Specialization
Citations

This map shows the geographic impact of Kang Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kang Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kang Lu more than expected).

Fields of papers citing papers by Kang Lu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kang Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kang Lu. The network helps show where Kang Lu may publish in the future.

Co-authorship network of co-authors of Kang Lu

This figure shows the co-authorship network connecting the top 25 collaborators of Kang Lu. A scholar is included among the top collaborators of Kang Lu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kang Lu. Kang Lu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Liu, Jiarui, Han Yang, Kang Lu, et al.. (2025). Exosome- transported FER inhibitor suppresses progression of diffuse large B-cell lymphoma via regulating AJUBA/Hippo axis. npj Precision Oncology. 9(1). 258–258.
2.
Bai, Jiaming, Cheng Luo, Kang Lu, et al.. (2025). Mechanical properties and fracture characteristics of a typical hard-to-deform superalloy GH4079 prepared by powder metallurgy technology. Journal of Materials Research and Technology. 39. 6254–6262.
3.
Zhang, Yang, Jun Ma, Peipei Li, et al.. (2025). Fatty acid metabolism shapes immune responses in chronic lymphocytic leukemia. Biomarker Research. 13(1). 42–42.
4.
Lu, Kang, et al.. (2025). Bifunctional platinum-based catalysts for electrochemical detection and conversion of glucose. Microchemical Journal. 212. 113389–113389. 1 indexed citations
5.
Jiang, Yujie, Xiao Lv, Xueling Ge, et al.. (2021). Wilms tumor gent 1 (WT1)-specific adoptive immunotherapy in hematologic diseases. International Immunopharmacology. 94. 107504–107504. 8 indexed citations
6.
Jia, Qiang‐Qiang, Hongyang Zhang, Kang Lu, et al.. (2021). Simultaneous quantification of eleven short-chain fatty acids by derivatization and solid phase microextraction - Gas chromatography tandem mass spectrometry. Journal of Chromatography A. 1661. 462680–462680. 19 indexed citations
7.
8.
Yao, Qingchun, Bo Li, Yongsheng Xie, et al.. (2020). Glycolysis is suppressed by DCZ0801-induced inactivation of the Akt/mTOR pathway in Multiple Myeloma. Journal of Cancer. 11(16). 4907–4916. 5 indexed citations
9.
Chen, Gege, Ke Hu, Haiguo Sun, et al.. (2020). A novel phosphoramide compound, DCZ0847, displays in vitro and in vivo anti-myeloma activity, alone or in combination with bortezomib. Cancer Letters. 478. 45–55. 7 indexed citations
10.
Hu, Liangning, Bo Li, Gege Chen, et al.. (2020). A novel M phase blocker, DCZ3301 enhances the sensitivity of bortezomib in resistant multiple myeloma through DNA damage and mitotic catastrophe. Journal of Experimental & Clinical Cancer Research. 39(1). 105–105. 7 indexed citations
11.
Zhang, Ting, Bo Li, Zhijian Xu, et al.. (2019). DCZ0801, a novel compound, induces cell apoptosis and cell cycle arrest via MAPK pathway in multiple myeloma. Acta Biochimica et Biophysica Sinica. 51(5). 517–523. 9 indexed citations
12.
Zhang, Ya, Xiangxiang Zhou, Ying Li, et al.. (2018). Inhibition of maternal embryonic leucine zipper kinase with OTSSP167 displays potent anti-leukemic effects in chronic lymphocytic leukemia. Oncogene. 37(41). 5520–5533. 43 indexed citations
13.
Lv, Xiao, Lili Feng, Xueling Ge, Kang Lu, & Xin Wang. (2016). Interleukin-9 promotes cell survival and drug resistance in diffuse large B-cell lymphoma. Journal of Experimental & Clinical Cancer Research. 35(1). 106–106. 40 indexed citations
14.
Lu, Kang, et al.. (2016). Bruton's tyrosine kinase inhibitor restrains Wnt signaling in chronic lymphocytic leukemia. Molecular Medicine Reports. 13(6). 4934–4938. 4 indexed citations
15.
Wang, Ling, Xianglu Li, Xinyu Liu, et al.. (2015). Enhancing effects of indirubin on the arsenic disulfide-induced apoptosis of human diffuse large B-cell lymphoma cells. Oncology Letters. 9(4). 1940–1946. 6 indexed citations
16.
Li, Peipei, Lili Feng, Na Chen, et al.. (2015). Metadherin contributes to the pathogenesis of chronic lymphocytic leukemia partially through Wnt/β-catenin pathway. Medical Oncology. 32(2). 479–479. 20 indexed citations
17.
Lu, Kang, Xiaosheng Fang, Lili Feng, et al.. (2015). The STAT3 inhibitor WP1066 reverses the resistance of chronic lymphocytic leukemia cells to histone deacetylase inhibitors induced by interleukin-6. Cancer Letters. 359(2). 250–258. 23 indexed citations
18.
Liu, Xinyu, Xianglu Li, Wang Ling, et al.. (2013). Realgar induces apoptosis in the chronic lymphocytic leukemia cell line MEC-1. Molecular Medicine Reports. 8(6). 1866–1870. 3 indexed citations
19.
Wang, Xuan, Xinyu Liu, Xianglu Li, et al.. (2013). Arsenic disulfide induces apoptosis of human diffuse large B cell lymphoma cells involving Bax cleavage. Oncology Reports. 30(5). 2427–2434. 7 indexed citations
20.
Lu, Kang & Xin Wang. (2012). Therapeutic advancement of chronic lymphocytic leukemia. Journal of Hematology & Oncology. 5(1). 55–55. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ilaria Buondonno Breakdown of academic impact, for papers by Kazuki Koizumi Breakdown of academic impact, for papers by Alexander Neuwelt Breakdown of academic impact, for papers by Xiangyuan Liu Breakdown of academic impact, for papers by Ken‐ichi Akamatsu Breakdown of academic impact, for papers by Michael Rosenbach Breakdown of academic impact, for papers by Thomas Plitz Breakdown of academic impact, for papers by Nan Lin Breakdown of academic impact, for papers by Geng Xu
Rankless by CCL
2026